Current Status of National Institutes of Health Research Funding for Women Surgeon-Scientists.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA surgery"
DOI: 10.1001/jamasurg.2022.5157
Abstract: Importance Women have made substantial advancements in academic surgery, but research funding disparities continue to hamper their progress, and current literature on the status of National Institutes of Health (NIH) funding awarded to women surgeon-scientists… read more here.
Keywords: surgeon scientists; number; research funding; women surgeon ... See more keywords
Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25864
Abstract: E.E.M.: Consulting fees from Adaptive Biotechnologies, Celgene, Takeda, Sanofi, Janssen; Research Funding to University of Texas MD Anderson from: Merck, Quest Diagnostics, Sanofi, JW Pharma. M.I.W.: consulting for Acerta Pharma, Janssen; Research Funding to UT… read more here.
Keywords: patients newly; methotrexate cytarabine; janssen; research funding ... See more keywords
ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.1_2632
Abstract: Roche, Janssen, Takeda, MSD, Gilead, Bristol Myers Squibb, AstraZenecca; Research Funding: Celgene, Roche, Abbvie; Other Remuneration: Roche, Amgen. Chu, M: Honoraria: AstraZeneca, Gilead, Celgene. Dreyling, M: Honoraria: Bayer, Celgene, Gilead, Janssen, Roche, Acerta, Bayer, Celgene,… read more here.
Keywords: janssen; roche; research funding; celgene ... See more keywords
MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.75_2631
Abstract: Research Funding: Acerta Pharma. Schuster, S: Consultant Advisory Role: Novartis, Nordic Nanovector, Celgene, Merck, Gilead, Pfizer; Honoraria: Genentech, Novartis, Nordic Nanovector, Celgene, Merck, OncLive, Dava Oncology, Physician's Education Source, LLC; Research Funding: Genentech, Novartis, Nordic… read more here.
Keywords: rituximab; oncology; celgene; research funding ... See more keywords
Creating a priority list of non-communicable diseases to support health research funding decision-making.
Sign Up to like & getrecommendations! Published in 2020 at "Health policy"
DOI: 10.1016/j.healthpol.2020.12.003
Abstract: OBJECTIVE To develop and pilot a framework based on multi-criteria decision analysis (MCDA) to prioritize non-communicable diseases (NCDs) to support health research funding decision-making. METHODS The framework involves identifying NCDs to be prioritized, specifying prioritization… read more here.
Keywords: decision; priority; research funding; cancer ... See more keywords
The politics of research impact: academic perceptions of the implications for research funding, motivation and quality
Sign Up to like & getrecommendations! Published in 2018 at "British Politics"
DOI: 10.1057/s41293-018-0077-9
Abstract: There is growing interest in demonstrating the societal and economic value of research around the world with the UK and Australia at the forefront of these developments. Characterised as an ‘impact agenda’, impact policies have… read more here.
Keywords: quality; research; academic perceptions; impact ... See more keywords
The modified lottery: Formalizing the intrinsic randomness of research funding.
Sign Up to like & getrecommendations! Published in 2021 at "Accountability in research"
DOI: 10.1080/08989621.2021.1927727
Abstract: Competition for research funds has, in the recent decade, become hypercompetitive. Commonly, to determine which proposals receive funding, a system of peer review is used, which is broadly accepted, easily understood, and broadly trusted among… read more here.
Keywords: research; modified lottery; funding; peer review ... See more keywords
Oral Health Research Funding in Relation to Disease Burden in Australia.
Sign Up to like & getrecommendations! Published in 2022 at "Australian dental journal"
DOI: 10.1111/adj.12949
Abstract: BACKGROUND This study aims to investigate and compare the major Australian government research funding schemes for oral health science with other disciplines from the burden of disease perspective. METHODS Major government research funding scheme outcomes… read more here.
Keywords: oral health; research funding; disease burden; funding ... See more keywords
Progressive multi‐focal leucoencephalopathy among ibrutinib‐treated persons with chronic lymphocytic leukaemia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.14322
Abstract: Wang: No relevant conflicts of interest. Morrissette: No relevant conflicts of interest. Lieberman: No relevant conflicts of interest. Timlin: No relevant conflicts of interest. Schuster: Nordic Nanovector: Membership on an entity’s Board of Directors or… read more here.
Keywords: consultancy research; relevant conflicts; research; research funding ... See more keywords
Rethinking research funding in pandemic times
Sign Up to like & getrecommendations! Published in 2020 at "Gender, Work and Organization"
DOI: 10.1111/gwao.12601
Abstract: Experiences from individualized gender equality funding programs, as the ones used in Denmark, demonstrate that one-off policy interventions, although a small step in the right direction, cannot stand alone in the fight against gender imbalances… read more here.
Keywords: rethinking research; gender; funding; research funding ... See more keywords
Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-177
Abstract: Bromodomain and extra-terminal protein (BETP) inhibitors (BETis) disrupt the chromatin binding and activity of the BETP BRD4 in facilitating RNA pol II-mediated mRNA transcription, thereby depleting levels of active oncoproteins including c-Myc, CDK6, BCL2, PIM1… read more here.
Keywords: consultancy; research; beti; research funding ... See more keywords